Back to top
more

Sanofi (SNY)

(Delayed Data from NSDQ)

$55.54 USD

55.54
1,761,011

-0.71 (-1.26%)

Updated Oct 3, 2024 04:00 PM ET

After-Market: $55.60 +0.06 (0.11%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 18% (45 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Regeneron (REGN), SNY Win EC Approval for Dupixent for COPD

by Zacks Equity Research

Regeneron (REGN) and partner Sanofi get approval for their blockbuster drug Dupixent for the chronic obstructive pulmonary disease indication in the EU.

Regeneron (REGN) Gets Positive CHMP Opinion for Lymphoma Drug

by Zacks Equity Research

Regeneron (REGN) gets positive CHMP recommendation for odronextamab for the treatment of adults with relapsed/refractory follicular lymphoma or diffuse large B-cell lymphoma.

AbbVie's (ABBV) Celsius Therapeutics Deal to Boost IBD Presence

by Zacks Equity Research

AbbVie's (ABBV) acquisition of Celsius Therapeutics is set to add the latter's lead pipeline candidate, CEL383, a potential first-in-class TREM1 inhibitor, to ABBV's pipeline.

Denali (DNLI) Outperforms Industry in 3 Months: Here's Why

by Zacks Equity Research

Denali (DNLI) gains 11.9% in three months on positive updates on its candidates.

Novavax (NVAX) Seeks Nod for Updated COVID-19 Jab in Europe

by Zacks Equity Research

Novavax (NVAX) seeks marketing authorization in the European Union for an updated version of its COVID-19 vaccine, which has been formulated to target the JN.1 variant.

AbbVie's (ABBV) Skyrizi Gets FDA Nod for Ulcerative Colitis

by Zacks Equity Research

AbbVie's (ABBV) Skyrizi is now approved for four indications across immune-mediated inflammatory diseases.

Regeneron (REGN) Outperforms Industry YTD: What Lies Ahead?

by Zacks Equity Research

Regeneron (REGN) maintains momentum on the back of Dupixent profits and efforts to develop oncology portfolio despite near-term challenges.

Novavax (NVAX) Seeks FDA Nod for Updated COVID-19 Vaccine

by Zacks Equity Research

Novavax (NVAX) seeks FDA???s approval to update its COVID-19 vaccine for the 2024-2025 fall season against current circulating strains, including KP.2 and KP.3.

AbbVie (ABBV) Buys Global Rights to Novel IBD Candidate

by Zacks Equity Research

AbbVie (ABBV) signs an exclusive global licensing deal with the Chinese company FutureGen to develop FG-M701, a next-generation TL1A antibody, for IBD indications.

Regeneron (REGN), SNY Win FDA Nod for Kevzara Label Expansion

by Zacks Equity Research

The FDA approves label expansion of Regeneron (REGN) and Sanofi's Kevzara for the treatment of polyarticular juvenile idiopathic arthritis.

Denali's (DNLI) Candidate Selected for FDA's START Pilot Program

by Zacks Equity Research

Denali's (DNLI) DNL126, an investigational enzyme replacement therapy, gets selected for the START Pilot Program, intended to accelerate the development of rare disease therapies.

TEVA Stock Rises 135% in a Year: What's Driving the Recovery?

by Zacks Equity Research

TEVA expects its newer drugs, Austedo, Uzedy and Ajovy, as well as a stable generics business, to help revive top-line growth in future quarters.

GSK Stock Dips on Delaware Court Ruling for Zantac Litigation

by Zacks Equity Research

GSK shares decline more than 7% in pre-market trading on Monday in response to an unfavorable ruling by a state court in Delaware in the Zantac litigation.

FDA Delays Decision on Sanofi (SNY)-Regeneron Dupixent in COPD

by Zacks Equity Research

Per the FDA, the data submitted by Sanofi (SNY)/Regeneron (REGN) for Dupixent in COPD indication constitutes a major amendment to its previously-submitted data. A final decision is expected by Sep 27.

Kinjel Shah headshot

Pharma Stock Roundup: JNJ, MRK M&A Deals, SNY, RHHBY Drugs' Priority Review & More

by Kinjel Shah

J&J (JNJ) and Merck (MRK) announce the acquisitions of private biotechs. The FDA grants Priority Review tags to Sanofi's (SNY) and Roche's (RHHBY) regulatory applications.

J&J (JNJ) to Buy Rights to Novel Atopic Dermatitis Candidate

by Zacks Equity Research

J&J (JNJ) is set to acquire Yellow Jersey Therapeutics, which holds NM26 rights, from Numab's shareholder, for a purchase price of $1.25 billion in cash.

Sanofi's (SNY) Sarclisa sBLA Gets FDA's Priority Review Tag

by Zacks Equity Research

The FDA grants priority review to Sanofi's (SNY) sBLA for the Sarclisa combination regimen for transplant-ineligible newly diagnosed multiple myeloma. A decision is due on Sep 27, 2024.

AstraZeneca (AZN) Plans to Generate $80B in Revenues by 2030

by Zacks Equity Research

AstraZeneca (AZN) targets $80 billion in total revenues by 2030. It expects to launch 20 new medicines.

Sanofi (SNY) Signs Deal for AI-Powered Drug Development

by Zacks Equity Research

Sanofi (SNY) inks collaboration deal with Formation Bio and OpenAI to build AI-powered software to advance drug development and create new medicines.

Why Novavax (NVAX) Stock Price Appreciated 14% on Monday

by Zacks Equity Research

Novavax (NVAX) surges after one of its top shareholders drops a proxy campaign against the company. This withdrawal is in sync with the company???s recently signed multi-billion-dollar deal with Sanofi.

The Zacks Analyst Blog Highlights Novavax, Sanofi, Fulcrum Therapeutics, Moderna and Bristol Myers

by Zacks Equity Research

Novavax, Sanofi, Fulcrum Therapeutics, Moderna and Bristol Myers are included in this Analyst Blog.

Sheraz Mian headshot

Top Analyst Reports for Oracle, Bank of America & McDonald's

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including Oracle Corporation (ORCL), Bank of America Corporation (BAC) and McDonald's Corporation (MCD), as well as two micro-cap stocks Miller Industries, Inc. (MLR) and Via Renewables, Inc. (VIA).

Ekta Bagri headshot

Biotech Stock Roundup: NVAX, FULC Up on Deals With SNY, Updates From MRNA, BMY

by Ekta Bagri

Novavax, Inc (NVAX) and Fulcrum Therapeutics, Inc (FULC) are in the spotlight following license agreements with pharma giant Sanofi.

Novavax (NVAX) Q1 Earnings Miss, Stock Soars on Sanofi Deal

by Zacks Equity Research

Novavax (NVAX) partners with Sanofi to market its COVID-19 vaccine and also develop novel COVID-19-influenza combination vaccines. This announcement even overshadows the dismal Q1 results.

Sanofi (SNY), Regeneron's Dupixent sBLA Gets FDA Priority Tag

by Zacks Equity Research

Sanofi (SNY) and Regeneron's (REGN) Dupixent is poised to be the first medicine for adolescents with inadequately controlled CRSwNP, if approved by the FDA.